Updates are available Correction dated 2023-03-19
Click to view Correction: https://doi.org/10.1007/s11096-023-01544-6
-
Authors
Lu, Xiaoyan https://orcid.org/0000-0002-5592-7239
Jarrett, James
Sadler, Susannah
Tan, Min
Dennis, James
Jairath, Vipul https://orcid.org/0000-0001-8603-898X
-
Funding
Funding for this research was provided by:
Galapagos NV
Gilead Sciences Europe Ltd
- License Information
-
More Information
Article History
Received: 12 April 2022
Accepted: 17 October 2022
First Online: 9 December 2022
Change Date: 19 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11096-023-01544-6
Conflicts of interest
: XL is an employee of Galapagos. JJ is an employee of Gilead Sciences Inc. SS and MT were employees of Health Economics and Outcomes Research Ltd at the time of the study. JD is an employee of Health Economics and Outcomes Research Ltd. VJ has received consulting/advisory board fees from AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda and TopiVert, and speaker’s fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, Shire and Takeda.
